Source of Support: None, Conflict of Interest: None
Since the first description of unusual symptoms of bone pains with peculiar urine by McIntyre (1850), great progress has been made in diagnosis and treatment of multiple myeloma and understanding of its behaviour. It still presents a therapeutic dilemma, since, the long term survivors are relatively uncommon. Though the quality of life is improved, our present study intends not only to elucidate the nature, magnitude and distribution of this uncommon disease in this region but to provide data and information which might help to evaluate the role of radiotherapy as an adjuvant to chemotherapy in terms of length of survival and quality of life. An attempt is also made to assess the relationship between certain characteristics of patients and response rates, remission periods and overall survivals.